13S150. Draft ACR/EULAR APLS Classif Crit #ACR22 Entry: Clinical & +aPL w/in 3 yr Then: Additive crit -Don't count other cause Clinical Domains: Macrovasc VTE, Macrovasc AT, Microvasc, Obst, Cardiac, Hematology Lab: +LA, aCL/B2GP IgM/IgG/titer Total: 3+ clin, 3+ lab @RheumNow https://t.co/YeKW0orjZC

Plenary: Tyrosine kinase 2 (TYK2) ◦ Mediates signaling of Type I IFNs, IL-23, and IL-12 ◦ Key cytokines involved in lupus pathogenesis ◦ Deucravacitinib oral TYK2 inhibitor ◦ Phase 2 RCT in SLE showed efficacy Pike M Abs1117 https://t.co/eJhNsM02Vl #ACR22 @RheumNow https://t.co/C6JQqR1DLj

• Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inh…

Carter et al. Case series showing rapid effect of anifrolumab in refractory discoid lupus and SCLE. @RheumNow #ACR22 Abstr#0974 https://t.co/RjnNxjGJoP…

• Rapid and Effective Response to Immunosuppression in Treating Macrophage Activa…

Are preexisting autoimmune dx pts okay for PD-1i/CTLA-4i combo immunoRx (vs PD-1i single agent)? Common question in practice for your rheum pts who get cancer Combo ICI means: de novo irAE: double risk flares: same risk Give our pts what they need! ABST0757 #ACR22 @RheumNow https://t.co/Vs1AoM54Ut

Zheng et al. Celiac disease more common in SLE aOR 2.88 (95%CI 2.60 –3.31). More common in white females. Assoc higher hospitalization cost and increased LOS @RheumNow #ACR22 Abstr#1192 https://t.co/kdwLmpIxNN https://t.co/ZdQJQn3QIF

• Celiac Disease in Patients with Systemic Lupus Erythematosus: An Analysis of Na…

Phase 2 efficacy and safety of deucravaticinib (TYK2i) in mod-severe SLE. Met primary endpoint (SRI4) for 3mg and 6mg doses (but not 12mg). No signal for HZ but increased oral herpes. Bigger numbers will be helpful. @RheumNow #ACR22 #plenary #ACRBest https://t.co/SjW1OSQzdM

DEUC showed statistically significant and sustained clinical efficacy in SRI(4) responses versus PBO and was well tolerated in SLE. Plenary Abs 1117 #ACR22 @RheumNow https://t.co/iHPiA8FCwO https://t.co/A0FQ7zwL64

• Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inh…

#ACR22 Plenary II Abstr#1117 Phase 2 results +ve in #lupus! Patients (65% White) on Deucravacitinib, TYK2-i had more SRI-4 response rates vs PBO. PBO:34.4%; DEUC 3 mg BID:58.2%, DEUC 6 mg BID:49.5%, DEUC 12 mg QD:44.9%. No major safety, slight increase in oral herpes @RheumNow https://t.co/QIJfoeP4dg

Costenbader @karen_kc123 7 year results VITAL. 2000iu vitamin D reduced autoimmune disease over 5 years; after trial end, effect dissipated and no longer overall significant. No change in borderline effect of 1000 mg/day omega3. @RheumNow #ACR22 Abstr#1200 https://t.co/lebdzWIO4n https://t.co/HKbHwLihrI

• Vitamin D and Marine n-3 Fatty Acid Supplementation for Prevention of Autoimmun…

Inverse association between average yearly HCQ dose and CV damage in cohort of SLE pts from Abs 0982 #ACR22 @RheumNow https://t.co/sfB6ONgwOa https://t.co/FAUGAVe2mB

• Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progressio…

Ab1115 #ACR22 Rx Co-Pay affects Rx Adherence in SLE Higher copays associated w/: 💊39% lower odds of HCQ adherence 💊56% lower AZA adherence 💊32% lower MMF adherence Need better $$ and transparency into costs. Screen for determinants of health affecting affordability! @Rheumnow https://t.co/1NdBb3GLzL

Serum AMH reduced in adolescents w/ rheumatic disease compared to menstrual-age matched, healthy controls. UCTD and SLE higher disease activity assoc'd w/ dec AMH levels, suggesting dz activity and dz may affect ovarian reserve. Abs 0942 #ACR22 @RheumNow https://t.co/xSZ85ipFSD https://t.co/tsaWBdrQcb

• Evaluation of Ovarian Reserve Using Anti-Mullerian Hormone Levels in Adolescent…

Excllent plenary, medication copay modifies treatment adherence in SLE >$10 copay reduced adherence for HCQ (39%), AZA (56%), MMF (32%) Easy to imagine that all our innovation cannot overcome access & barriers Should be priority to fix #ACR22 @RheumNow #ACRBest Abstr#1115 https://t.co/BPfr9mCVgy